Last reviewed · How we verify
Switch to TDF/FTC/RPV after 24 weeks
A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents.
A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents. Used for HIV-1 infection in treatment-experienced or treatment-naive patients.
At a glance
| Generic name | Switch to TDF/FTC/RPV after 24 weeks |
|---|---|
| Also known as | Eviplera(r) |
| Sponsor | Azienda Ospedaliera San Gerardo di Monza |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TDF (tenofovir disoproxil fumarate) and FTC (emtricitabine) are nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, while RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor that binds directly to the enzyme. Together, these three agents provide potent suppression of HIV viral replication through dual inhibition of reverse transcriptase.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive patients
Common side effects
- Nausea
- Headache
- Diarrhea
- Rash
- Renal impairment (TDF-related)
- Bone density loss (TDF-related)
Key clinical trials
- Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
- Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: